Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 8/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77855 | 0.92 | CYP3A4 (0.52) | CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL10066408 | 0.89 | CYP3A4 (0.43) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL77863 | 0.81 | CYP2C19 (0.67) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1086021 | 0.80 | CYP2C19 (0.55) | CYP2C9CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL287920 | 0.78 | CYP2C19 (0.50) | CYP2C9CYP2C19CYP3A4CYP2D6BRAF | |
| SCHEMBL298458 | 0.77 | CYP2C19 (0.46) | CYP2C9CYP2C19CYP3A4CYP2D6BRAF | |
| SCHEMBL297948 | 0.77 | CYP3A4 (0.49) | CYP2C9CYP2C19CYP3A4CYP2D6BRAF | |
| SCHEMBL298612 | 0.77 | CYP2C19 (0.51) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL12655351 | 0.76 | CYP3A4 (0.71) | CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL298712 | 0.75 | CYP2C9 (0.46) | CYP2C9CYP2C19CYP3A4CYP2D6BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2C9 1862/4885CYP2C19 1818/4885CYP3A4 3037/4885 |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2C9 1862/4885CYP2C19 1818/4885CYP3A4 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.